Philip DeSouza, M.D.

Philip DeSouza, M.D., is a venture partner at Newpath Partners, a life science venture firm with a mission to translate groundbreaking scientific discoveries into transformative treatments for patients. At Newpath, Dr. DeSouza leads scientific and technical due diligence, identifies, evaluates, and ultimately licenses promising intellectual property, and heads market landscape analysis. Dr. DeSouza has served as acting CEO and CMO for several stealth and early-stage Newpath portfolio companies. In addition to serving on the board of Autobahn, he is a board observer at Nvelop Therapeutics. Dr. DeSouza has received prestigious national research grants, resulting in several patented and marketed technologies. He has co-authored numerous scientific manuscripts in high-impact journals, including one that became the basis for a Newpath portfolio company. A licensed, board-certified vitreoretinal surgeon, Dr. DeSouza earned his M.D. from Duke University. He completed his ophthalmology residency at Wake Forest University as co- chief resident, and his vitreoretinal surgery fellowship at the University of California, Davis.